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AbstrACt 
Introduction Closed-loop systems titrate insulin based on 
sensor glucose levels, providing novel means to reduce the 
risk of hypoglycaemia while improving glycaemic control. 
We will assess effectiveness of 6-month day-and-night 
closed-loop insulin delivery compared with usual care 
(conventional or sensor-augmented pump therapy) in 
children and adolescents with type 1 diabetes.
Methods and analysis The trial adopts an open-label, 
multicentre, multinational (UK and USA), randomised, 
single-period, parallel design. Participants (n=130) are 
children and adolescents (aged ≥6 and <19 years) with 
type 1 diabetes for at least 1 year, and insulin pump 
use for at least 3 months with suboptimal glycaemic 
control (glycated haemoglobin ≥58 mmol/mol (7.5%) and 
≤86 mmol/mol (10%)). After a 2–3 week run-in period, 
participants will be randomised to 6-month use of hybrid 
closed-loop insulin delivery, or to usual care. Analyses will 
be conducted on an intention-to-treat basis. The primary 
outcome is glycated haemoglobin at 6 months. Other 
key endpoints include time in the target glucose range 
(3.9–10 mmol/L, 70–180 mg/dL), mean sensor glucose 
and time spent above and below target. Secondary 
outcomes include SD and coefficient of variation of 
sensor glucose levels, time with sensor glucose levels 
<3.5 mmol/L (63 mg/dL) and <3.0 mmol/L (54 mg/dL), 
area under the curve of glucose <3.5 mmol/L (63 mg/
dL), time with glucose levels >16.7 mmol/L (300 mg/dL), 
area under the curve of glucose >10.0 mmol/L (180 mg/
dL), total, basal and bolus insulin dose, body mass index 
z-score and blood pressure. Cognitive, emotional and 
behavioural characteristics of participants and caregivers 
and their responses to the closed-loop and clinical trial will 
be assessed. An incremental cost-effectiveness ratio for 
closed-loop will be estimated.
Ethics and dissemination Cambridge South Research 
Ethics Committee and Jaeb Center for Health Research 
Institutional Review Office approved the study. The 
strengths and limitations of this study
 ► The study adopts an open-label, multicentre, mul-
tinational, randomised, parallel design: it includes a 
large group of children and adolescents across wide 
geographical locations.
 ► The trial adopts a 6-month follow-up period of hy-
brid closed-loop insulin delivery during unrestricted 
living.
 ► Participants in the two study groups will have an 
equal number of study visits.
 ► The study design excludes participants with re-
current incidents of severe hypoglycaemia or dia-
betic ketoacidosis during the previous 6 months, 
living alone  and those with glycated haemoglobin 
<58 mmol/mol (7.5%) and >86 mmol/mol (10%) 
and with high or very low daily insulin requirements 
(total daily insulin dose ≥2 IU/kg/day or <15 IU/day).
 ► All participants are already pump users, somewhat 
limiting generalisability.
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findings will be disseminated by peer-review publications and conference 
presentations.
trial registration number NCT02925299; Pre-results.
IntroduCtIon
Type 1 diabetes is characterised by a deficiency of insulin 
caused by immunologically mediated damage to pancre-
atic beta cells, leading to raised blood glucose levels. 
Diabetes is one of the most common metabolic condi-
tions. It is estimated that in 2017, 1 100 000 children and 
adolescents (0–19 years) worldwide had type 1 diabetes 
and that the number of newly diagnosed cases was over 
130 000.1 The incidence rate in children is increasing by 
~3%–4% per year with geographic differences.1 Earlier 
onset can result in diabetes complications appearing 
at a younger age, while dependence on lifelong insulin 
imposes a heavy burden on children, carers as well as 
healthcare systems.
Despite continuing progress, glycaemic control in chil-
dren and adolescents with type 1 diabetes remains subop-
timal.2 The achievement of recommended treatment goals 
is limited by the risk of hypoglycaemia. Even in those with 
the desired level of glycaemic control, non-physiological 
glucose excursions occur with periods of silent hypergly-
caemia and hypoglycaemia.3 4 Individuals have blunted 
counter-regulatory responses to hypoglycaemia impairing 
recovery and increasing the threat of future episodes.5 
Recurrent episodes may lead to hypoglycaemic unaware-
ness, increasing the risk of severe hypoglycaemia.6 Hypo-
glycaemia has psychological consequences including the 
fear of hypoglycaemia with resulting maladaptive coping 
behaviours, such as excessive eating or under-insulinising, 
that may negatively impact glycaemic control.7
The development of continuous glucose monitoring 
has been a major advance.8–11 Sensor-augmented pumps 
combine real-time continuous glucose monitoring with 
insulin pump.12 Insulin pumps with low-glucose suspend 
feature have been shown to reduce hypoglycaemia.13 
These systems, however, overall provide little or no 
automation to adjust insulin delivery to match glucose 
excursions.
An artificial pancreas (a closed-loop system) adjusts 
insulin automatically and represents a realistic treat-
ment option for type 1 diabetes.14 The closed-loop 
control algorithm translates, in real-time, sensor glucose 
levels received from the glucose monitoring device and 
computes the amount of insulin to be delivered by the 
coupled insulin pump. Hybrid closed-loop systems 
automatically titrate insulin delivery, although the user 
manages insulin boosts at meal time.15 In 2017, the first 
closed-loop system entered clinical use in the USA.16
Closed-loop systems may improve glycaemic control 
while reducing the risk of hypoglycaemia.17 They have 
been evaluated in children and adolescents under 
controlled laboratory conditions18–20 and in home 
settings.21–24 Investigations in adults have also been 
conducted.22 25 26 Psychosocial assessments support 
acceptability and benefits of this therapeutic approach 
among children/adolescents and carers.27 Closed-loop 
systems are associated with increased time in near normo-
glycaemia and reduced time in hypoglycaemia and hyper-
glycaemia.28 So far, evaluations have been limited to 3 
months.22
The present study will assess the efficacy, safety, utility 
and acceptability of 6-month day-and-night hybrid closed-
loop insulin delivery during unrestricted living in compar-
ison to usual care in children and adolescents with type 
1 diabetes.
MEthods And AnAlysIs
overview
This trial adopts an open-label, multicentre, multina-
tional, single-period, randomised, parallel group design, 
involving a 6-month home study period during which 
day-and-night glucose levels will be managed either by 
a closed-loop system (intervention group) or by insulin 
pump therapy (control group) (figure 1). We aim to 
recruit up to 150 children and adolescents aged ≥6 to 
<19 years with type 1 diabetes on insulin pump therapy 
(approximately equal proportion of those aged ≥6 to 
12 years and 13 to <19 years, a minimum quota of 
25% participants with baseline glycated haemoglobin 
Figure 1 Study flowchart. HbA1c, glycated haemoglobin; 
CGM, continuous glucose monitoring.  
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>69 mmol/mol, >8.5%). Inclusion and exclusion criteria 
are summarised in box 1.
The University of Cambridge (UK) and Jaeb Center 
for Health Research (USA) are the coordinating centres. 
Clinical centres include:
1. Addenbrooke’s Hospital, Cambridge, UK.
2. Barbara Davis Center for Childhood Diabetes, Aurora, 
USA.
3. Indiana University, Indianapolis, USA.
4. Leeds Teaching Hospital, Leeds, UK.
5. Nottingham Children's Hospital, Nottingham, UK.
6. Southampton Children’s Hospital, Southampton, UK.
7. Stanford University, Stanford, California, USA.
8. Yale University, New Haven, Connecticut, USA.
Cognitive, emotional and behavioural characteristics of 
participants and family members and their response to the 
closed-loop will be assessed gathering both quantitative 
(validated surveys) and qualitative data (focus groups). 
Written informed consent/assent will be obtained from 
all participants and guardians before any study-related 
activities.
study schedule
The study will comprise up to eight visits and six tele-
phone/email contacts (see tables 1 and 2). The maximum 
study duration is 8 months.
screening and baseline assessment
At screening, blood samples for full blood count, liver, 
thyroid function and anti-transglutaminase antibodies 
(with IgA levels if not done within previous 12 months) 
will be taken. Non-hypoglycaemia C-peptide, glucose and 
glycated haemoglobin will be measured and a urine preg-
nancy test in females of childbearing potential will be 
performed. Surveys investigating participants’ quality of 
life, psychosocial and cognitive functioning, and response 
to their current treatment will be distributed. Participants 
will be fitted with a blinded continuous glucose moni-
toring device (Libre Pro, Abbott Diabetes Care, Alameda, 
CA, USA) that will be worn during the run-in period at 
home for up to 14 days.
run-in period
During a 2–3 week run-in period, subjects will continue 
using their own insulin pump. Data obtained from 
blinded glucose sensors and pump downloads may be 
utilised for treatment adjustments. The run-in period 
may be extended/repeated if no or limited sensor data 
are available. At least 10 days of sensor data need to be 
collected. A longer run-in will not be used for additional 
fine-tuning of treatment adjustments.
randomisation
Central randomisation software will be used with strati-
fication by site and baseline glycated haemoglobin. The 
randomisation ratio will be 1:1 within each stratum. The 
randomisation list created by the study statistician is 
encrypted.
box 1 Inclusion and exclusion criteria
Summary of inclusion criteria
 ► Age ≥6 and <19 years.
 ► Type 1 diabetes as defined by WHO34 for at least 1 year.
 ► Use of an insulin pump for at least 3 months, with good knowledge 
of insulin self-adjustment by subject or caregiver as judged by the 
investigator.
 ► Using U-100 rapid acting insulin analogues Aspart or Lispro only.
 ► Willing to perform regular finger-prick blood glucose monitoring, 
with at least 4 blood glucose measurements per day.
 ► Screening glycated haemoglobin  ≥58 mmol/mol (7.5%) 
and ≤86 mmol/mol (10%) based on analysis from local laboratory.
 ► Literate in English.
 ► Willing to wear continuous glucose sensor and closed-loop system 
at home.
 ► Willing to follow study-specific instructions.
 ► Willing to upload pump and glucose sensor data at regular intervals.
 ► Access to Wi-Fi.
 ► Living with someone who is trained to administer glucagon and is 
able to seek emergency assistance.
Summary of exclusion criteria
 ► Living alone.
 ► Current use of any closed-loop system.
 ► Any other physical or psychological disease likely to interfere with 
the normal conduct of the study and interpretation of the study re-
sults, as judged by the investigator.
 ► Untreated coeliac disease, adrenal insufficiency or untreated thyroid 
disease.
 ► Current treatment with drugs known to interfere with glucose me-
tabolism (eg, systemic corticosteroids, non-selective beta-blockers, 
monoamine oxidase inhibitors and so on).
 ► Known or suspected allergy to insulin.
 ► Clinically significant nephropathy (estimated glomerular filtration 
rate <45 mL/min) or on dialysis, neuropathy or active retinopathy 
(presence of maculopathy or proliferative changes), as judged by 
the investigator.
 ► Recurrent incidents of severe hypoglycaemia (>1 episode) during 
the previous 6 months (adolescents: severe hypoglycaemia is de-
fined as an event requiring assistance of another person to actively 
administer carbohydrates, glucagon or take other corrective actions 
including episodes of hypoglycaemia severe enough to cause un-
consciousness, seizures or attendance at hospital; children: severe 
hypoglycaemia is defined as an event associated with a seizure or 
loss of consciousness).
 ► Recurrent incidents of diabetic ketoacidosis (>1 episode) during the 
previous 6 months.
 ► Unwilling to avoid regular use of acetaminophen.
 ► Lack of reliable telephone facility for contact.
 ► Total daily insulin dose ≥2 IU/kg/day and <15 IU/day.
 ► Pregnancy, planned pregnancy or breast feeding.
 ► Severe visual or hearing impairment.
 ► Seizure disorder.
 ► Medically documented allergy towards the adhesive (glue) of 
plasters or unable to tolerate tape adhesive in the area of sensor 
placement.
 ► Serious skin diseases (eg, psoriasis vulgaris, bacterial skin diseas-
es) located at places of the body likely to be used for localisation of 
the glucose sensor.
 ► Abusing illicit drugs, prescription drugs or alcohol.
Continued
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treatment period
Automated day-and-night hybrid closed-loop insulin delivery 
combined with low-glucose suspend feature (interventional arm)
Participants allocated to the closed-loop group will 
be trained on using the study insulin pump (modi-
fied Medtronic 640G pump, Medtronic, Northridge, 
CA, USA) and real-time continuous glucose sensor 
(Guardian 3, Medtronic). This represents a complex 
intervention over usual care, especially for subjects 
under pump therapy alone. Once deemed competent 
with the use of the devices, participants will receive 
training required for the closed-loop system. Compe-
tency on the use of closed-loop will be evaluated. During 
closed-loop period, participants will programme meal 
boluses estimating ingested carbohydrate amounts. 
Specific instructions during closed-loop related to exer-
cise management, sick day rules, hypoglycaemia and 
hyperglycaemia management and technical trouble-
shooting will be provided.
Usual care (conventional or sensor-augmented pump therapy) 
(control arm)
Participants in control arm will receive refresher training 
on key aspects of insulin pump therapy (advanced boluses, 
temporary basal, infusion set change, sensor calibrations). 
During 6-month control intervention period, subjects will 
continue using either their own insulin pump alone or 
combined with their prestudy glucose monitoring device.
box 1 Continued
 ► Use of pramlintide (Symlin), or other non-insulin glucose lowering 
agents including sulphonylureas, biguanides, dipeptidyl peptidase-4 
(DPP4) inhibitors, glucagon-like peptide-1 (GLP-1) analogues, sodi-
um-glucose cotransporter (SGLT)-1/2 inhibitors at time of screening.
 ► Shift work with working hours between 22:00 and 08:00.
 ► Sickle cell disease, haemoglobinopathy or has received red blood 
cell transfusion or erythropoietin within 3 months prior to time of 
screening.
 ► Eating disorder such as anorexia or bulimia.
 ► Employed by Medtronic Diabetes or with immediate family mem-
bers employed by Medtronic Diabetes.
Table 1 Schedule of study visits/phone contacts when the participant is randomised to day-and-night closed-loop combined 
with low-glucose feature (intervention group)
Visit/
contact Description
Start relative to previous/next visit/
activity Duration (hours)
Run-in Visit 1 Recruitment visit: consent, HbA1c, screening 
bloods, urine pregnancy test, baseline surveys, 
blinded CGM training and insertion
1–4
Visit 2 Review of baseline bloods, pump settings and 
CGM data; adjustment of treatment
2 weeks after visit 1 (+1 week); run-in could 
be repeated
1–2
Training
period
Visit 3 Randomisation, repeat HbA1c if visit 3 and 
visit 1 are >28 days apart, urine pregnancy test, 
study pump training and initiation, competency 
assessment
May coincide with visit 2, within 8 weeks 
of visit 1
3–4
Visit 3a Real-time CGM training and initiation, 
competency assessment
Within 0–7 days of visit 3 (visit 3a may 
coincide with visit 3; training visits can be 
repeated)
2–4
CL + LGS
intervention
(6 months)
Visit 4* CL initiation at clinic/home: data download, CL 
and low-glucose feature training, competency 
assessment, blinded CGM
4 weeks after randomisation (±1 week) 2–6
Contact 1 Review use of study devices; study update Within 24–48 hours after visit 4 <1
Visit 5† Review use of study devices; study update 1 week after visit 4 (±3 days) <1
Contact 2 Review use of study devices; study update 2 weeks after visit 4 (±3 days) <1
Contact 3 Review use of study devices; study update 1 month after visit 4 (±2 weeks) <1
Contact 4 Review use of study devices; study update 2 months after visit 4 (±2 weeks) <1
Visit 6 3 month visit: HbA1c, urine pregnancy test, data 
download, blinded CGM, surveys
4 months after randomisation (±2 weeks) 1–3
Contact 5 Review use of study devices; study update 5 months after randomisation (±2 weeks) <1
Contact 6 Review use of study devices; study update 6 months after randomisation (±2 weeks) <1
Visit 7 Blinded CGM 2–4 weeks before planned visit 8 <0.5
Visit 8 End of closed-loop treatment arm (6 months of 
CL): HbA1c, data download, surveys and focus 
groups; resume usual pump therapy
7 months after randomisation (±2 weeks) 1–3
*In-person clinic visit mandatory in USA only.
†Could be done via phone/email in UK. In-person visit mandatory in USA only.
CGM, continuous glucose monitoring; CL, closed-loop; HbA1c, glycated haemoglobin; LGS, low-glucose suspend. 
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At the study initiation visit, participants in both study 
groups will be fitted with a blinded continuous glucose 
monitoring system (Libre Pro) that will be worn for up 
to 14 days. If the sensor fails or gets detached, another 
sensor may be inserted. The sensor data may be used to 
optimise insulin delivery.
Assessments at 3 and 6 months
A blood sample will be collected for measurement of 
glycated haemoglobin. A urine pregnancy test in females 
of childbearing potential will be performed. As per usual 
clinical practice, glucometer downloads and pump data 
will be reviewed, and adjustments to insulin pump settings 
will be made as required. Validated surveys evaluating the 
impact of the devices employed on quality of life, psycho-
social and cognitive functioning, diabetes management 
and treatment satisfaction will be administered. At the 
3-month follow-up visit, participants in both study groups 
will be fitted with blinded continuous glucose monitoring 
systems (Libre Pro). For assessment of glycaemic control 
during the final 3-month period of the trial, partici-
pants in both study groups will be fitted with a blinded 
continuous glucose monitoring system 2–4 weeks before 
the end of study. At the 6-month visit, the same proce-
dures as at the 3-month visit will be followed. A subset of 
subjects/guardians will be invited to join follow-up focus 
groups.
study contacts during 6-month study period
Participants in the two study groups will have an equal 
number of contact visits. The first planned contact will 
occur within 24–48 hours after study initiation visit. 
During the first 2 weeks of the study period, participants 
will be contacted weekly. Thereafter, participants will be 
contacted monthly. Subjects/parents and/or the clinical 
team are free to adjust insulin therapy, but no active treat-
ment optimisation will be undertaken by the research 
team.
devices download
As per usual care, insulin pump and blood glucose meter 
will be downloaded (Medtronic CareLink) every clinic 
visit (at least every 3 months).
Table 2 Schedule of study visits/phone contacts when the participant is randomised to usual care (conventional or sensor-
augmented insulin pump therapy) (control group)
Visit/contact Description
Start relative to previous/next visit/
activity Duration (hours)
Run-in Visit 1 Recruitment visit: consent, HbA1c, screening 
bloods, urine pregnancy test, baseline 
surveys, blinded CGM training and insertion
1–4
Visit 2 Review of baseline bloods, pump settings 
and CGM data; adjustment of treatment
2 weeks after visit 1 (+1 week); run-in 
could be repeated
1–2
Training period Visit 3 Randomisation, repeat HbA1c if visit 3 and 
visit 1 are >28 days apart, urine pregnancy 
test, insulin pump refresher training, 
competency assessment
May coincide with visit 2, within 8 weeks 
of visit 1
3–4
Usual insulin pump 
therapy
intervention
(6 months)
Visit 4* Initiation of standard therapy arm at clinic/
home, glucometer download, recording of 
current insulin requirements, blinded CGM
4 weeks after randomisation (±1 week) 2–6
Contact 1 Study update Within 24–48 hours after visit 4 <1
Visit 5† Study update 1 week after visit 4 (±3 days) <1
Contact 2 Study update 2 weeks after visit 4 (±3 days) <1
Contact 3 Study update 1 month after visit 4 (±2 weeks) <1
Contact 4 Study update 2 months after visit 4 (±2 weeks) <1
Visit 6 3-month visit: HbA1c, urine pregnancy test, 
glucometer download, recording of current 
insulin requirements, surveys, blinded CGM
4 months after randomisation (±2 weeks) 1–3
Contact 5 Study update 5 months after randomisation (±2 weeks) <1
Contact 6 Study update 6 months after randomisation (±2 weeks) <1
Visit 7 Blinded CGM 2–4 weeks before planned visit 8 <0.5
Visit 8 End of standard pump therapy treatment arm 
(6 months): HbA1c, glucometer download, 
recording of current insulin requirements, 
surveys and focus groups, resume usual care
7 months after randomisation (±2 weeks) 1–3
*In-person clinic visit mandatory in USA only.
†Could be done via phone/email.
CGM, continuous glucose monitoring; HbA1c, glycated haemoglobin.
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Closed-loop system
The FlorenceM closed-loop system (figure 2) incorpo-
rates a computer-based algorithm hosted by an Android 
smartphone, which interacts wirelessly with the modified 
investigational-use-only 640G pump through a proprietary 
translator device included in the smartphone’s enclo-
sure. By using the information received from the glucose 
sensor, every 10 min the system computes a new tempo-
rary basal insulin infusion rate, which is automatically sent 
to the insulin pump. The treat-to-target control algorithm 
aims to achieve a default glucose level of 5.8 mmol/L 
(104 mg/dL) and regulates the actual level depending 
on fasting versus postprandial status and the accuracy of 
model-based glucose predictions. No remote monitoring 
is planned. While the system is charging and connected 
to internet, the device uploads data on a server. The study 
pump comprises continuous glucose monitoring receiver 
and provides hypoglycaemia and hyperglycaemia alarms, 
which can be activated/personalised by the participants.
safety precautions during closed-loop
Participants will be asked to perform capillary calibra-
tions before breakfast and dinner. If sensor glucose value 
is >3.0 mmol/L (54 mg/dL) different from capillary 
glucose level, the sensor will be recalibrated. These direc-
tions are based on an in silico simulation of hypoglycaemia 
and hyperglycaemia risk using the validated Cambridge 
simulator.29 If sensor glucose becomes unavailable or the 
smartphone is not in range/operational, the pump will 
automatically deliver the preprogrammed insulin as set 
on the pump within 30 min. Safety rules limit maximum 
insulin infusion and suspend insulin delivery when 
sensor glucose is ≤4.3 mmol/L (77 mg/dL) or when 
glucose is rapidly decreasing. In case of a communica-
tion failure between control algorithm device and the 
study pump, the low-glucose feature will interrupt insulin 
delivery, provided sensor glucose is available. Low-glu-
cose suspend/predictive low-glucose management will be 
initially set to suspend insulin delivery at sensor glucose 
values of 3.9 mmol/L (70 mg/dL) or less, after which the 
setting could range from 2.8 to 5.0 mmol/L (50–90 mg/
dL). Predictive low-glucose suspend will not be used. 
Insulin delivery will be resumed in accordance of the 
low-glucose suspend feature implemented on the study 
pump. A 24-hour local telephone helpline will be avail-
able for any technical device issues or problems related to 
diabetes management.
Participant withdrawal criteria
The following prerandomisation withdrawal criteria will 
apply:
1. Subject/caregiver is unable to demonstrate safe use of 
study insulin pump as judged by the investigator.
2. Subject/caregiver fails to demonstrate compliance 
with insulin pump and capillary self-monitoring of 
blood glucose during run-in.
Prerandomisation and postrandomisation withdrawal 
criteria will comprise:
1. Subjects/caregivers may terminate participation in the 
study at any time without necessarily giving a reason 
and without any personal disadvantage.
2. Significant protocol violation or non-compliance.
3. Two distinct episodes of severe hypoglycaemia.
4. Two distinct episodes of diabetic ketoacidosis unrelat-
ed to infusion site failure and related to the use of the 
closed-loop.
5. Decision by the investigator or the sponsor that termi-
nation is in the subject's best medical interest.
6. Allergic reaction to insulin.
7. Allergic reaction to adhesive surface of infusion set or 
glucose sensor.
8. Subject becomes pregnant during the study period.
Subjects withdrawn due to reasons 4–10 will be invited 
to provide blood sample at the end of the planned study 
intervention for the assessment of glycated haemoglobin.
Figure 2 FlorenceM closed-loop system prototype. The system consists of a continuous glucose monitoring transmitter with 
Guardian 3 sensor (Medtronic), an insulin pump (modified 640G pump, Medtronic) and an Android smartphone running the 
control algorithm (Cambridge).
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Psychosocial evaluations
Cognitive, emotional and behavioural characteristics 
of participating subjects and family members and their 
response to the closed-loop system and clinical trial will 
be assessed using validated surveys and focus groups. 
Surveys will be completed at baseline (prior to randomis-
ation), at 3 and 6 months.
To assess how strongly participants value the benefits 
of the closed-loop (compared with the usual care), we 
will conduct a discrete choice experiment (DCE). In the 
DCE, respondents will answer a series of binary choice 
questions (eg, ‘Given a choice between option A or B, 
which would you prefer…') where those two options offer 
differing strengths and weaknesses. By varying the perfor-
mance levels of these different desirable characteristics, 
we can assess their relative importance.
Focus groups will be completed at the end of the study 
(6 months). We will conduct virtual focus groups using 
HIPAA-approved software supported by Stanford Univer-
sity. Focus groups will be run with three to six participants 
and we will work from a script of open-ended questions 
used to gather feedback and reactions to the closed-
loop system/insulin pump therapy, the clinical trial and 
quality of life changes. Sessions will be audio taped and 
video taped and transcribed by a professional transcrip-
tion service.
blood samples
Screening blood samples will be measured locally. Addi-
tional blood samples will be taken for the measurement 
of non-hypoglycaemia C-peptide and glycated haemo-
globin at a central laboratory. Glycated haemoglobin will 
be assessed at baseline, 3 and 6 months. At each time 
point, glycated haemoglobin will be measured locally 
(clinical care) and centrally (analysis of study endpoints). 
The central analysis will be performed using an Interna-
tional Federation of Clinical Chemistry and Laboratory 
Medicine aligned method.
Patient and public involvement
The research question and study endpoints are based on 
feedback from participants of previous studies and in line 
with prioritising by stakeholders.30 The study design and 
the assessment of the burden of the intervention were 
reviewed by focus groups. Results will be disseminated to 
participants and general public through social media and 
will be made available on the sponsor's website.
statistical analysis
Primary outcome analysis
The primary analysis will follow the intention-to-treat 
principle. Data from all randomised subjects will be anal-
ysed in the group to which the subjects were assigned 
through randomisation regardless of the actual treat-
ment received. Data will not be truncated due to protocol 
deviations.
The primary analysis will evaluate between group 
differences in glycated haemoglobin levels at the end of 
treatment period. A 5% significance level will be consid-
ered statistically significant for the primary outcome 
comparison.
Mean±SD values or percentiles appropriate to the distri-
bution will be reported for the primary outcome by treat-
ment group. The two treatment groups will be compared 
using a linear regression model adjusting for glycated 
haemoglobin at baseline, age and clinical centre as random 
effect. A 95% CI will be reported for the difference between 
the randomisation groups based on the linear regression 
model. Residual values will be examined for an approx-
imate normal distribution. If values are highly skewed, 
then a transformation or robust statistical methods (eg, 
non-parametric or MM estimation) will be used instead. A 
detailed analysis plan will be provided separately.
Other key endpoints
For the following key endpoints at 6 months, the family-
wise type I error rate will be controlled at two-sided α=0.05. 
A gatekeeping strategy will be used, where the primary 
endpoint will be tested first, if passing the significance 
testing, other key endpoints will be tested in the order listed 
below using the fixed-sequence method at α=0.05.
 ► Time spent in the target glucose range from 3.9 to 
10.0 mmol/L (70–180 mg/dL).
 ► Mean sensor glucose.
 ► Time spent above target glucose 10.0 mmol/L 
(180 mg/dL).
 ► Time spent below target glucose 3.9 mmol/L (70 mg/
dL).
If a non-significant (p>0.05) result is obtained for any 
outcome on this list, no further hypothesis testing will be 
performed for any metrics further down on the list.
Secondary efficacy analyses
For these exploratory analyses, the false discovery rate will 
be used to account for multiple comparisons:
Continuous glucose monitoring derived indices
 ► SD of sensor glucose.
 ► Sensor glucose variability measured with the coeffi-
cient of variation.
 ► The time with glucose <3.5 mmol/L (63 mg/dL).
 ► The time with glucose <3.0 mmol/L (54 mg/dL).
 ► Area under the curve of glucose <3.5 mmol/L (63 mg/
dL).
 ► The time spent in significant hyperglycaemia 
(glucose >16.7 mmol/L, 300 mg/dL).
 ► Area under the curve of glucose >10.0 mmol/L 
(180 mg/dL).
The following sensor glucose metrics will also be calcu-
lated separately for day-time period (06:00–23:59) and 
night-time period (00:00–05:59):
 ► The time with glucose from 3.9 to 10.0 mmol/L 
(70–180 mg/dL).
 ► Mean glucose.
 ► Glucose variability as measured by SD.
 ► The time with glucose <3.5 mmol/L (63 mg/dL).
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Binary metrics for glycated haemoglobin
 ► HbA1c <53 mmol/mol (7.0%).
 ► HbA1c <58 mmol/mol (7.5%).
 ► Relative reduction ≥10% from baseline.
 ► Absolute reduction ≥0.5% from baseline.
 ► Absolute reduction ≥1% from baseline.
 ► Absolute reduction ≥1% from baseline or 
HbA1c<53 mmol/mol (7.0%).
Insulin and other endpoints
 ► Total, basal and bolus insulin dose.
 ► Body weight (body mass index z-score).
 ► Blood pressure.
The above described glycaemic metrics will be based on 
sensor glucose levels collected during postrandomisation 
periods of blinded sensors wear.
safety analyses
The following events will be recorded and compared 
between treatment groups:
 ► Number of severe hypoglycaemia events per subject 
and incidence rate per 100 person-years.
 ► Number of diabetic ketoacidosis events per subject 
and incidence rate per 100 person-years.
 ► Sensor glucose-measured hypoglycaemic events per 
week (>15 min with glucose <3 mmol/L, 54 mg/dL).
 ► Sensor glucose-measured hyperglycaemic events per 
week (>15 min with glucose >16.7 mmol/L, 300 mg/
dL).
 ► Proportion of subjects with worsening of glycated 
haemoglobin from baseline to 6 months by >0.5%.
If we record enough observed events to allow formal 
statistical modelling for above safety outcomes, we will 
perform the following analyses. Poisson regression 
models will be constructed to compare the treatment 
group difference for event rates by adjusting for age, base-
line glycated haemoglobin and random site effect. If any 
outlier exists, a robust Poisson regression model will be 
used instead. For binary glycated haemoglobin outcome, 
logistic regression models will be used to compare the 
treatment group difference by adjusting for age, baseline 
glycated haemoglobin and random site effect.
utility assessments
The following system use/function outcomes in the inter-
vention arm will be tabulated:
 ► Number of low-glucose suspend events.
 ► Percentage of time when closed-loop system use is 
functioning.
 ► Percentage of time when continuous glucose moni-
toring is used.
subgroup analyses
No subgroups were considered during the power calcu-
lations. Interpretation of any subgroup analyses will 
depend on whether the overall analysis demonstrates a 
significant treatment group difference. In the absence of 
such difference, if performed, the subgroup analyses will 
be interpreted with caution.
Psychosocial analyses
Quantitative data on usability and satisfaction will be 
analysed using simple descriptive statistics. Additionally, 
we will analyse scores from the cognitive, emotional and 
behavioural assessments to determine if changes occur 
over time and between groups.
We will construct predictive models in the general 
linear framework to examine the associations with 
primary outcomes. For the DCE, the strength of prefer-
ence (importance) of each performance attribute will be 
estimated from the pooled DCE responses using standard 
regression analysis techniques.
Qualitative data will be analysed using  Atlas. ti V.6.0 to 
organise and manage the entire corpus of focus group 
data.
Cost utility analyses
To inform reimbursement and other policy deci-
sion-making, we will conduct a cost utility analysis on 
the benefits of closed-loop. The analysis timeframe for 
both costs and benefits will include not just the study 
period but also anticipated future impacts. Costs will be 
denominated in US$. They will be framed to include both 
health-related expenditures and any realised or projected 
incremental health cost savings. Utility will be quantified 
in quality-adjusted life years. We will elicit health-related 
quality of life during the study period using two prefer-
ence based measures of health status: the Child Health 
Utility 9D31 and the EuroQol 5D-Y.32 Future health and 
cost impacts, beyond the study period, will be estimated 
using numerical modelling. Incremental cost effective-
ness ratios, comparing the closed-loop system to usual 
care will be calculated.
Interim analysis
We will not perform an interim analysis.
Perprotocol analysis
We will conduct a perprotocol analysis in order to repli-
cate the primary analysis, but limited to participants who 
did not withdraw from the study (withdrawals excluded 
even if they return for a 6-month glycated haemoglobin 
measurement) and used closed-loop for at least 70% of 
the time (intervention group).
Power calculation
Data from the JDRF Continuous Glucose Monitoring 
Randomised Clinical Trial (JDRF CGM RCT)33 from 
subjects who would have met the eligibility criteria for 
the current trial were used to project the distribution 
of baseline and 6-month glycated haemoglobin. Among 
n=53 subjects meeting the eligibility criteria in the JDRF 
CGM RCT (n=20 subjects 8–12 years of age and n=33 
subjects 13–18 years of age), the upper limit of the CI for 
the effective SD of glycated haemoglobin was 0.71%. With 
this effective SD, for a true 0.4% reduction in glycated 
haemoglobin, power=85%, two-sided type 1 error=5%, 
1:1 randomisation, total sample size is estimated to be 
116. Adding 10% for potential dropout/non-compliance 
9Musolino G, et al. BMJ Open 2019;9:e027856. doi:10.1136/bmjopen-2018-027856
Open access
results in a final total sample size of ~128 (64 in each 
treatment group).
study MAnAgEMEnt
data safety Monitoring board
A Data Safety Monitoring Board (DSMB) will be insti-
tuted. The DSMB will be notified of all serious adverse 
events and any unanticipated adverse device effects/
events and will perform regular safety data review. The 
DSMB will report to the National Institute of Diabetes 
and Digestive and Kidney Diseases (the Funder) any 
safety concerns and recommendations for suspension or 
early termination of the trial.
study sponsors
In the UK, the study sponsors are the University of 
Cambridge and the Cambridge University Hospitals NHS 
Foundation Trust. Study sponsor in the USA is the Jaeb 
Center for Health Research.
study management committee
A study management committee composed of the chief 
investigator, study coordinators and study data manager 
will meet monthly to discuss the operational aspects of 
the trial.
data management and monitoring
Designated personnel from coordinating centres will be 
responsible for maintaining quality assurance and quality 
control systems to ensure that the trial is conducted and 
data are generated, documented and reported in compli-
ance with the protocol, Good Clinical Practice and regu-
latory requirements.
We will observe confidentiality of subject data. Personal 
details for each participant with a link to a unique identi-
fication number will be held locally on a study screening 
log in the Trial Master File at each of the investigation 
centres. These details will not be disclosed at any other 
stage during the study, and all individual results will 
remain anonymous.
Indemnity
Indemnity for any harm rising on the conduct of research 
will be provided according to arrangements in respective 
countries:
1. UK—any liability arising from study design will be cov-
ered by clinical trial insurance policy organised by the 
University of Cambridge. National Health Service in-
demnity cover will apply for any claims arising from 
management and conduct of research.
2. USA—any liability arising from study design will be un-
der the responsibility of the participants or their insur-
ance company.
EthICs And dIssEMInAtIon
The study has undergone a review by regulatory author-
ities in the UK (Medicines and Healthcare products 
Regulatory Agency) and in the USA (Food and Drug 
Administration). All participants will be provided with 
oral and written information about the trial and proce-
dures involved in the study before obtaining written 
informed consent. For minors, parents/guardians will 
provide written informed consent, and written assent will 
be gained.
Standard operating procedures for monitoring and 
reporting of all adverse events and adverse device effects 
will be in place including serious adverse events, serious 
adverse device effects and specific adverse events, such 
as severe hypoglycaemia and significant hyperglycaemia 
with ketosis.
Any substantial amendments to the protocol and other 
documents shall be submitted to, and approved by, the 
Independent Research Ethics Committee/Institutional 
Review Board and the regulatory authorities, prior to 
implementation as per nationally agreed guidelines.
The study started enrolling participants in June 2017 
and is expected to complete clinical follow-up by January 
2020 and to report results in 2020. Trial results will be 
disseminated in internationally peer-reviewed scientific 
journals.
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